[Psychopharmacological therapy of self-injurious behavior in mentally retarded individuals].
Neurobiological research has implicated the dopamine and serotonin system in the pathogenesis of self-injurious behavior. The efficacy of antipsychotic drugs has been questioned. Opened and controlled investigations have shown risperidone is effective for reducing self-injurious behaviour in mentally retardation. We report about 3 mentally retarded patients which were given open-label risperidone for 12 weeks. They participated in a detailed assessment of behaviour symptoms at baseline and the repetitive behaviour was weekly rated with the disability assessment schedule (DAS). All three patients responded.
Hässler
F
F
Klinik für Kinder- und Jugendneuropsychiatrie der Universität Rostock.
Fegert
J M
JM
D000328:Adult; D018492:Dopamine Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008607:Intellectual Disability / Q000150:complications*; D008297:Male; D011569:Psychiatric Status Rating Scales; D018967:Risperidone / Q000008:administration & dosage / Q000627:therapeutic use*; D016728:Self-Injurious Behavior / Q000150:complications / Q000188:drug therapy*; D012702:Serotonin Antagonists / Q000008:administration & dosage / Q000627:therapeutic use*; D016896:Treatment Outcome
D018492:Dopamine Antagonists; D012702:Serotonin Antagonists; D018967:Risperidone
Psychopharmakotherapie des selbstverletzenden Verhaltens bei Menschen mit geistiger Behinderung.